Six studies were included (n=1,327 patients): four RCTs (n=1,055 patients) and two case-control studies (n=272 patients). Two of the RCTs were double-blinded and the assessor was blinded in a third RCT.
Compared to follitropin alfa FbIU, follitropin alfa FbM was associated with improvements in the following outcomes: a significantly lower dose (WMD -230.29 IU, 95% CI -326 to -134.5; four studies, n=1,019); significantly fewer days of treatment (WMD –0.48, 95% CI -0.69 to -0.27; five studies, n=1,150); significantly greater number of oocytes (WMD 0.84, 95% CI 0.18 to 1.51; five studies, n=1,150); and a significantly greater number of embryos (WMD 0.88, 95% CI 0.40 to 1.37; three studies, n=875).
There was no statistically significant difference between follitropin alfa FbM and FbIU in the number of follicles greater than 14mm (three studies, n=403), number of clinical pregnancies (three studies, n=558) or cases of OHSS (four studies, n=1,128).
Follitropin alfa FbM was associated with a significantly higher peak level of oestradiol (WMD 613.08pmol/L, 95% CI 142.4 to 1083.7; five studies, n=1,150).
No significant heterogeneity was found for any of the analyses (I2<50%).